{"id":3048,"date":"2023-07-07T18:00:34","date_gmt":"2023-07-07T21:00:34","guid":{"rendered":"https:\/\/www.zalikafarmaceutica.com\/?p=3048"},"modified":"2024-12-09T11:00:31","modified_gmt":"2024-12-09T14:00:31","slug":"nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe","status":"publish","type":"post","link":"https:\/\/www.zalikafarmaceutica.com\/pt\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/","title":{"rendered":"Nuvaxovid COVID-19 Vaccine Receives Full Authorization in Europe"},"content":{"rendered":"<p>(Precision Vaccinations)<\/p>\n<p>Novavax, Inc. announced yesterday that its protein-based COVID-19 vaccine had been granted full Marketing Authorization (MA) by the European Commission in the European Union (EU).<\/p>\n<p>The Nuvaxovid\u2122 (NVX-CoV2373) vaccine is now fully authorized for use in the EU as a primary series in individuals aged 12 and older.<\/p>\n<p>And as a booster dose in adults aged 18 and older to prevent COVID-19.<\/p>\n<p>During the <span style=\"color: #ffffff;\"><a style=\"color: #ffffff;\" href=\"https:\/\/www.vaxbeforetravel.com\/2023\/07\/06\/covid-19-related-fatalities-continue-decreasing\"><strong>diminishing pandemic<\/strong><\/a><\/span>, Novavax&#8217;s COVID vaccine has been authorized for use in more than 40 markets worldwide.<\/p>\n<p>&#8220;This Marketing Authorization establishes the foundation for all future regulatory approvals for updated versions of our COVID vaccine, a necessity to ensure we can quickly get our vaccine to individuals in the EU,&#8221; said John C. Jacobs, President and Chief Executive Officer, Novavax, in a <span style=\"color: #ffffff;\"><strong><a style=\"color: #ffffff;\" href=\"https:\/\/novavax.investorroom.com\/2023-07-06-Novavaxs-Nuvaxovid-TM-Receives-Full-Marketing-Authorization-in-the-EU-for-the-Prevention-of-COVID\">press release<\/a><\/strong><\/span> on July 6, 2023.<\/p>\n<p>&#8220;In addition to the EU, we are preparing to file for full approval in the U.S. and other markets and are committed to ensuring protein-based options are available worldwide.&#8221;<\/p>\n<p>&#8220;Vaccine choice remains an integral part of public health measures.&#8221;<\/p>\n<p>The U.S. Food and Drug Administration has not yet approved the trade name Nuvaxovid\u2122, nor has it been approved or licensed.<\/p>\n<p>However, as of July 7, 2023, it has been authorized for emergency use under an Emergency Use Authorization for various people. In Europe, <a href=\"https:\/\/www.precisionvaccinations.com\/vaccines\/covid-19-vaccines\"><span style=\"color: #ffffff;\"><strong>over ten COVID-19 vaccines<\/strong><\/span><\/a> are available.<\/p>\n<p>\u2014<span style=\"color: #ffffff;\"><strong><a style=\"color: #ffffff;\" href=\"https:\/\/www.precisionvaccinations.com\/people\/don-ward-hackett\">Don Ward Hackett<\/a><\/strong><\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>(Precision Vaccinations) Novavax, Inc. announced yesterday that its protein-based COVID-19 [&hellip;]<\/p>","protected":false},"author":1,"featured_media":3049,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[102],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nuvaxovid COVID-19 Vaccine Received Full Authorization in UE<\/title>\n<meta name=\"description\" content=\"The Nuvaxovid (NVX-CoV2373) vaccine is now fully authorized for use in the EU as a primary series in individuals aged 12 and older. Read more!\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.zalikafarmaceutica.com\/pt\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuvaxovid COVID-19 Vaccine Received Full Authorization in UE\" \/>\n<meta property=\"og:description\" content=\"The Nuvaxovid (NVX-CoV2373) vaccine is now fully authorized for use in the EU as a primary series in individuals aged 12 and older. Read more!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.zalikafarmaceutica.com\/pt\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"Zalika Farmac\u00eautica\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-07T21:00:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-09T14:00:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.zalikafarmaceutica.com\/wp-content\/uploads\/2023\/07\/flags-Zalika-Farmaceutica-Precision-Vaccinations-by-Bruno-P.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nuvaxovid COVID-19 Vaccine Receives Full Authorization in Europe\",\"datePublished\":\"2023-07-07T21:00:34+00:00\",\"dateModified\":\"2024-12-09T14:00:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/\"},\"wordCount\":228,\"publisher\":{\"@id\":\"https:\/\/www.zalikafarmaceutica.com\/#organization\"},\"keywords\":[\"Nuvaxovid vaccinessavelives vacinassalvamvidas pharmaceutical industry public health vaccine vaccination vaccinedevelopment vaccines saudepublica vacinas vacina\u00e7\u00e3o\"],\"articleSection\":[\"News\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/\",\"url\":\"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/\",\"name\":\"Nuvaxovid COVID-19 Vaccine Received Full Authorization in UE\",\"isPartOf\":{\"@id\":\"https:\/\/www.zalikafarmaceutica.com\/#website\"},\"datePublished\":\"2023-07-07T21:00:34+00:00\",\"dateModified\":\"2024-12-09T14:00:31+00:00\",\"description\":\"The Nuvaxovid (NVX-CoV2373) vaccine is now fully authorized for use in the EU as a primary series in individuals aged 12 and older. Read more!\",\"breadcrumb\":{\"@id\":\"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.zalikafarmaceutica.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nuvaxovid COVID-19 Vaccine Receives Full Authorization in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.zalikafarmaceutica.com\/#website\",\"url\":\"https:\/\/www.zalikafarmaceutica.com\/\",\"name\":\"Zalika Farmac\u00eautica\",\"description\":\"The Brazilian Healthcare Market within your hands!\",\"publisher\":{\"@id\":\"https:\/\/www.zalikafarmaceutica.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.zalikafarmaceutica.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.zalikafarmaceutica.com\/#organization\",\"name\":\"Zalika Farmac\u00eautica\",\"url\":\"https:\/\/www.zalikafarmaceutica.com\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/www.zalikafarmaceutica.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.zalikafarmaceutica.com\/wp-content\/uploads\/2022\/08\/zalika-farmaceutica.png\",\"contentUrl\":\"https:\/\/www.zalikafarmaceutica.com\/wp-content\/uploads\/2022\/08\/zalika-farmaceutica.png\",\"width\":979,\"height\":111,\"caption\":\"Zalika Farmac\u00eautica\"},\"image\":{\"@id\":\"https:\/\/www.zalikafarmaceutica.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\/\/www.zalikafarmaceutica.com\/pt\/author\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nuvaxovid COVID-19 Vaccine Received Full Authorization in UE","description":"The Nuvaxovid (NVX-CoV2373) vaccine is now fully authorized for use in the EU as a primary series in individuals aged 12 and older. Read more!","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.zalikafarmaceutica.com\/pt\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/","og_locale":"pt_BR","og_type":"article","og_title":"Nuvaxovid COVID-19 Vaccine Received Full Authorization in UE","og_description":"The Nuvaxovid (NVX-CoV2373) vaccine is now fully authorized for use in the EU as a primary series in individuals aged 12 and older. Read more!","og_url":"https:\/\/www.zalikafarmaceutica.com\/pt\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/","og_site_name":"Zalika Farmac\u00eautica","article_published_time":"2023-07-07T21:00:34+00:00","article_modified_time":"2024-12-09T14:00:31+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/www.zalikafarmaceutica.com\/wp-content\/uploads\/2023\/07\/flags-Zalika-Farmaceutica-Precision-Vaccinations-by-Bruno-P.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"","Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/#article","isPartOf":{"@id":"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/"},"author":{"name":"","@id":""},"headline":"Nuvaxovid COVID-19 Vaccine Receives Full Authorization in Europe","datePublished":"2023-07-07T21:00:34+00:00","dateModified":"2024-12-09T14:00:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/"},"wordCount":228,"publisher":{"@id":"https:\/\/www.zalikafarmaceutica.com\/#organization"},"keywords":["Nuvaxovid vaccinessavelives vacinassalvamvidas pharmaceutical industry public health vaccine vaccination vaccinedevelopment vaccines saudepublica vacinas vacina\u00e7\u00e3o"],"articleSection":["News"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/","url":"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/","name":"Nuvaxovid COVID-19 Vaccine Received Full Authorization in UE","isPartOf":{"@id":"https:\/\/www.zalikafarmaceutica.com\/#website"},"datePublished":"2023-07-07T21:00:34+00:00","dateModified":"2024-12-09T14:00:31+00:00","description":"The Nuvaxovid (NVX-CoV2373) vaccine is now fully authorized for use in the EU as a primary series in individuals aged 12 and older. Read more!","breadcrumb":{"@id":"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.zalikafarmaceutica.com\/2023\/07\/07\/nuvaxovid-covid-19-vaccine-receives-full-authorization-in-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.zalikafarmaceutica.com\/"},{"@type":"ListItem","position":2,"name":"Nuvaxovid COVID-19 Vaccine Receives Full Authorization in Europe"}]},{"@type":"WebSite","@id":"https:\/\/www.zalikafarmaceutica.com\/#website","url":"https:\/\/www.zalikafarmaceutica.com\/","name":"Zalika Farmac\u00eautica","description":"The Brazilian Healthcare Market within your hands!","publisher":{"@id":"https:\/\/www.zalikafarmaceutica.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.zalikafarmaceutica.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.zalikafarmaceutica.com\/#organization","name":"Zalika Farmac\u00eautica","url":"https:\/\/www.zalikafarmaceutica.com\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.zalikafarmaceutica.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.zalikafarmaceutica.com\/wp-content\/uploads\/2022\/08\/zalika-farmaceutica.png","contentUrl":"https:\/\/www.zalikafarmaceutica.com\/wp-content\/uploads\/2022\/08\/zalika-farmaceutica.png","width":979,"height":111,"caption":"Zalika Farmac\u00eautica"},"image":{"@id":"https:\/\/www.zalikafarmaceutica.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/www.zalikafarmaceutica.com\/pt\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/www.zalikafarmaceutica.com\/pt\/wp-json\/wp\/v2\/posts\/3048"}],"collection":[{"href":"https:\/\/www.zalikafarmaceutica.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.zalikafarmaceutica.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.zalikafarmaceutica.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.zalikafarmaceutica.com\/pt\/wp-json\/wp\/v2\/comments?post=3048"}],"version-history":[{"count":1,"href":"https:\/\/www.zalikafarmaceutica.com\/pt\/wp-json\/wp\/v2\/posts\/3048\/revisions"}],"predecessor-version":[{"id":3050,"href":"https:\/\/www.zalikafarmaceutica.com\/pt\/wp-json\/wp\/v2\/posts\/3048\/revisions\/3050"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.zalikafarmaceutica.com\/pt\/wp-json\/wp\/v2\/media\/3049"}],"wp:attachment":[{"href":"https:\/\/www.zalikafarmaceutica.com\/pt\/wp-json\/wp\/v2\/media?parent=3048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.zalikafarmaceutica.com\/pt\/wp-json\/wp\/v2\/categories?post=3048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.zalikafarmaceutica.com\/pt\/wp-json\/wp\/v2\/tags?post=3048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}